Cite
Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy.
MLA
Foss-Freitas, Maria C., et al. “Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy.” Diabetes Care, vol. 47, no. 4, Apr. 2024, pp. 653–59. EBSCOhost, https://doi.org/10.2337/dc23-1614.
APA
Foss-Freitas, M. C., Imam, S., Neidert, A., Gomes, A. D., Broome, D. T., & Oral, E. A. (2024). Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy. Diabetes Care, 47(4), 653–659. https://doi.org/10.2337/dc23-1614
Chicago
Foss-Freitas, Maria C., Salman Imam, Adam Neidert, Anabela Dill Gomes, David T. Broome, and Elif A. Oral. 2024. “Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy.” Diabetes Care 47 (4): 653–59. doi:10.2337/dc23-1614.